Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
Korro Bio, Inc. (KRRO)
Company Research
Source: GlobeNewswire
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs) Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration in a preclinical mouse modelEnded 2023 with a strong balance sheet of $166 million of cash and cash equivalents, including $117 million of proceeds from a successful private financing completed in November 2023Cash runway into 2026, which enables key readouts for KRRO-110 and progression of additional pipeline candidates CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for t
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at HC Wainwright from $115.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.MarketBeat
- Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical OfficerGlobeNewswire
- Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer [Yahoo! Finance]Yahoo! Finance
- Korro Announces $70 Million Private PlacementGlobeNewswire
KRRO
Earnings
- 5/14/24 - Miss
KRRO
Sec Filings
- 5/14/24 - Form 3
- 5/14/24 - Form S-1
- 5/14/24 - Form 424B3
- KRRO's page on the SEC website